Browse News
Filter News
Found 545 articles
-
Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2023 Financial Results
11/2/2023
Aligos Therapeutics, Inc. (Nasdaq: ALGS), a clinical stage biopharmaceutical company focused on developing novel therapeutics to address unmet medical needs in liver and viral diseases, today reported recent business progress and financial results for the third quarter 2023.
-
Dr. Jon Weidanz, MPH, Ph.D., Joins BioNTX Board of Directors
10/30/2023
BioNTX, the bioscience and healthcare innovation trade organization in North Texas, is proud to announce the appointment of Jon Weidanz, MPH, Ph.D., as its newest member of the Board of Directors.
-
REHEVA BIOSCIENCES SUCCESSFULLY COMPLETES RH324 PHASE I CLINICAL TRIAL FOR ADVANCED NON-SMALL CELL LUNG CANCER
10/25/2023
ReHeva Biosciences, a pioneering biopharmaceutical startup with the mission to help people live longer and healthier with cancer through naturally derived complex drugs, proudly announces the successful completion of its Phase I Safety Trial for its novel drug, RH324.
-
American Diabetes Association elevates health technology innovation through inaugural event in Silicon Valley
10/3/2023
The American Diabetes Association® invites life science leaders, business professionals, angel investors and venture capitalists to the 28th Annual Leaders Forum HealthTech Showcase on November 3, 2023, from 10:00 am to 1:30 pm PT at the Marriott in San Mateo, California.
-
LabShares Acquired by Life Sciences Industry Veteran Philip Borden and Pacific Lake Partners
9/12/2023
LabShares announced that life sciences industry veteran Philip Borden and investor Pacific Lake Partners have acquired a majority stake in the company.
-
AceLink Opens First Clinical Site in China for Phase 2 Study in Fabry Disease
8/10/2023
AceLink Therapeutics, Inc. announced the opening of the first clinical trial site in China for its Phase 2, open‑label study of the safety, pharmacokinetics, pharmacodynamics and preliminary measures of physiological efficacy of AL01211 in males with classic Fabry disease who have not been previously treated with other Fabry disease therapies.
-
Renalytix Reports Financial Results for Third Quarter of Fiscal Year 2023
6/9/2023
Renalytix plc today reported financial results for the fiscal third quarter ended March 31, 2023.
-
The Foundation for the National Institutes of Health Announces the Appointment of Jay Bradner, M.D. and Jim Weiss to the Board of Directors
5/22/2023
The Foundation for the National Institutes of Health is proud to announce two new additions to the FNIH Board of Directors, Dr. Jay Bradner and Jim Weiss.
-
Aligos Therapeutics Reports Recent Business Progress and First Quarter 2023 Financial Results
5/4/2023
Aligos Therapeutics, Inc. reported recent business progress and financial results for the first quarter 2023.
-
In addition to promoting their brands, companies say their funding initiatives give them access to the expertise of top researchers and contribute to society.
-
Renalytix Reports Second Quarter and First Half Fiscal Year 2023 Financial Results
3/30/2023
Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care, today reported financial results for the fiscal second quarter and first half ended December 31, 2022.
-
Know Labs Announces Executive Leadership Changes and Confirms 2023 Outlook
1/27/2023
Know Labs, Inc. (NYSE American: KNW), an emerging developer of non-invasive medical diagnostic technology, today announced changes to its executive leadership team.
-
Inotiv, Inc. Announces Fourth Quarter and Full Year Fiscal 2022 Financial Results
1/10/2023
Inotiv, Inc. today announced financial results for the three months (“Q4 FY 2022”) and twelve months (“FY 2022”) ended September 30, 2022.
-
If you want to maximize your career earnings, it pays to consider which cities are the most affordable. Here are the top five most affordable cities for biopharma in the U.S.
-
Renalytix Reports Financial Results for First Quarter of Fiscal Year 2023
11/30/2022
Renalytix plc today reported financial results for the fiscal first quarter ended September 30, 2022.
-
Botanical Solution Inc. (BSI) & Croda Pharma Partnership Agreement to Accelerate Production for GMP QS-21
11/30/2022
Botanical Solution Inc. (BSI), innovator of sustainable, consistent and cost-effective Advanced Botanical Materials (ABM) for agricultural and pharmaceutical applications, has entered into a Partnership Agreement with Croda Pharma to build a robust, scalable and truly sustainable supply chain and deliver kilogram-quantities of QS-21 to the pharmaceutical industry.
-
Cancer Biomarkers Market Size - Quantitative Research By QYResearch Medical
11/17/2022
The global cancer biomarkers market size was USD 27.83 Billion in 2021, and is expected to register a revenue CAGR of 17.6% during the forecast period.
-
A former steel industry giant, the 21st century Pittsburgh is a global life sciences hub, transforming research, technology and startups into a thriving center for innovation.
-
Precision Oncology Market Size up to 2030 - Quantitative Research by QYResearch Medical
11/15/2022
The global Precision Oncology market is forecasted to grow at a rate of 9.9% from USD 49.98 billion in 2019 to USD 99.72 billion in 2030.
-
Omniscient Neurotechnology Appoints Two New Members to Its Board of Directors
10/24/2022
Omniscient Neurotechnology, the brain mapping company creating new possibilities in brain health, today announced the appointment of Barbara Nelson and Surbhi Sarna to its board of directors.